Sanofi MS Drug’s Mixed Verdict at FDA Panel Puzzles Analysts

Sanofi’s multiple sclerosis drug Lemtrada is effective for preventing flare-ups of the disease, U.S. regulatory advisers said yesterday, even as they decided the company’s trials weren’t adequate to assess the drug.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.